The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raghuraman, G.
Right arrow Articles by Wang, C.-R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raghuraman, G.
Right arrow Articles by Wang, C.-R.
The Journal of Immunology, 2006, 177: 7841-7848.
Copyright © 2006 by The American Association of Immunologists, Inc.

IFN-beta-Mediated Up-Regulation of CD1d in Bacteria-Infected APCs1

Gayatri Raghuraman, Yanbiao Geng and Chyung-Ru Wang2

Department of Pathology, University of Chicago, Chicago, IL 60637


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The expression of CD1d molecules is essential for the selection and activation of a unique subset of T cells, invariant NKT cells, which express limited TCR diversity and have been demonstrated to function in both regulatory and antimicrobial immune responses. Although it has been reported that the levels of CD1d expression can be modulated during infection, the mechanisms that mediate this effect are poorly defined. In this study, we show that infection of dendritic cells and macrophages both in vitro and in vivo with the intracellular pathogen Listeria monocytogenes leads to up-regulation of CD1d. IFN-beta is required to mediate this up-regulation in L. monocytogenes infection, as well as being sufficient to up-regulate CD1d expression in vitro. Unlike MHC class I molecules, the increased surface expression of CD1d by IFN-beta is not regulated at the transcriptional level. Confocal microscopy and metabolic labeling experiments show that the total pool of CD1d protein is increased in IFN-beta-treated cells and that increased surface expression of CD1d is not due to the redistribution of the intracellular pool of CD1d. IFN-beta treatment increases the de novo synthesis of CD1d. This change in surface CD1d expression was functionally relevant, as IFN-beta-treated dendritic cells are more efficient in stimulating invariant NKT cells than untreated controls. Taken together, these data support a role for early IFN-beta-mediated up-regulation of CD1d in NKT cell activation during infection.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The CD1 family of proteins comprises a third lineage of Ag presentation molecules that present lipid, glycolipid, or lipopeptide Ags to T cells. CD1d is expressed in both mice and humans, in particular in cells of the hemopoietic lineage, including B cells, T cells, macrophages, and dendritic cells (DCs)3 (1, 2, 3). CD1d molecules are structurally homologous to MHC class I proteins, having similar domain structure as well as associating with beta2-microglobulin (beta2m) (4). The Ag-binding groove of these molecules differs, however, in that the CD1d groove is narrow and highly hydrophobic. CD1d can present either microbial or self-lipids/glycolipids to a unique subset of T cells, NKT cells (1, 5). The lipid Ags are loaded onto CD1d in a number of cellular compartments, including late endosomes, lysosomes, and the MHC class II containing compartments (6). Recent studies have identified several lipid transfer proteins that may regulate this process. Microsomal triglyceride transfer protein has been shown to function as an endoplasmic reticulum chaperone by loading endogenous lipids onto nascent CD1d (7, 8), while lipid transfer proteins including saposins and GM2 activators may facilitate exchange and loading of antigenic lipids onto CD1d in these endocytic compartments (9, 10).

Most CD1d-restricted NKT cells express an invariant V{alpha}14-J{alpha}18 TCR (invariant NKT (iNKT)) and can be activated by a marine sponge-derived glycolipid {alpha}-galactosylceramide ({alpha}-GalCer) (5, 11, 12, 13). A similar population of iNKT cells, expressing a V{alpha}24-J{alpha}18 TCR, is also present in humans (14). Upon activation, iNKT cells promptly produce large amounts of IL-4 and IFN-{gamma}, which can subsequently affect a variety of cell types and influence both innate and adaptive immune responses (15, 16, 17). Variable CD1d-restricted NKT cells, in contrast, exhibit greater TCR diversity and do not respond to {alpha}-GalCer (18, 19, 20, 21). Recent studies reveal that these two subsets of NKT cells may have distinct roles in tumor immunity and infection (22). Although it is not clear how variable CD1d-restricted NKT cells are activated during infection, it has been demonstrated that iNKT cells respond to microbial stimuli by two different mechanisms (23, 24). First, the TCR of iNKT cells can directly recognize microbial glycolipids presented by CD1d. These microbial Ags include mycobacterial phosphatidylinositol tetramannoside and Sphingomonas-derived glycolipids (25, 26, 27, 28). Second, as has been shown to be the case in Salmonella infection, the activation of NKT cells can be mediated by the recognition of self-lipid Ags presented by CD1d in combination with secondary signals. These secondary signals may include cytokines like IL-12 produced by APCs activated by microbial products as a result of TLR signaling (24, 28). This indirect mechanism allows NKT cells to respond to a wide variety of microbes. It is thus possible that changes in CD1d expression levels during inflammation may influence the extent of NKT cell responses, irrespective of whether self or microbial Ags are presented by CD1d.

Indeed, recent studies have shown that CD1d levels are altered during infections and inflammatory conditions. Oral infection with Salmonella enterica leads to increased CD1d expression on DC in vitro (29), whereas infection with Mycobacterium tuberculosis synergizes with inflammatory cytokines like IFN-{gamma} and TNF-{alpha}, leading to increased CD1d levels on macrophages (30). Furthermore, CD1d expression is markedly elevated on hepatocytes during hepatitis C virus infection (31). In contrast, Kaposi sarcoma-associated HSV infection has been shown to cause the loss of CD1d surface expression, which may provide a strategy for viral evasion of immune response (32). Taken together, these studies support the notion that modulation of CD1d expression during infection may have functional consequences on NKT cell response. Yet, the molecular and cellular mechanisms that regulate CD1d expression during infection are not clearly defined.

Listeria monocytogenes (LM), a Gram-positive facultative intracellular bacteria, provides an excellent model for probing cell-mediated immunity to infection (33). It has been shown that iNKT cells can contribute to a Th1 response in LM infection (34), but the role of CD1d expression in this response has not been explored. In this study, we analyzed the regulation of CD1d expression during LM infection. We found that the CD1d surface expression is up-regulated on DCs and macrophages during the early phase of LM infection. This effect is not directly mediated by LM, as conditioned medium from LM-infected DCs (LM-CM) also induced uninfected APCs to express higher levels of CD1d. Neutralization of LM-CM with Abs to IFN-beta significantly blocked CD1d up-regulation, suggesting IFN-beta is the major mediator for CD1d induction in this model. Indeed, administration of rIFN-beta enhanced CD1d surface expression on DCs in a dose-dependent manner. The IFN-beta treatment did not affect the transcription or the intracellular trafficking of CD1d, but instead, resulted in CD1d protein synthesis. Furthermore, IFN-beta-treated DCs are more efficient in activating iNKT than untreated controls. These data suggest that increased expression of CD1d on DCs is capable of promoting the immune response mediated by iNKT cells. Taken together, our results suggest that IFN-beta secreted early during infection and the resultant increase in CD1d expression may play a role in NKT cell activation and the subsequent LM-induced immune responses.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice and cells

Wild-type (WT) C57BL/6 were purchased from The Jackson Laboratory. V{alpha}14Tg mice bred in a C57BL/6 background were provided by Dr. A. Bendelac (University of Chicago, Chicago, IL). The generation of Kb-CD1dTg mice has been described (35). All animal work was approved by the University of Chicago Institutional Animal Care and Use Committee. Bone marrow-derived DCs (BMDCs) were generated as described previously by culturing in the presence of GM-CSF and IL-4 for 6 days (35). The DC cell line DC2.4 was provided by Dr. K. Rock (University of Massachusetts, Worcester, MA) (36). All the cells were grown in RPMI 1640 medium containing 2 mM L-glutamine, 100 U/ml penicillin, 50 µg/ml streptomycin sulfate, 50 µM 2-ME, and 10% FBS (RPMI 10).

Abs and reagents

The following Abs used were purchased from BD Pharmingen: FITC-conjugated anti-hamster IgG, PE-conjugated anti-F4/80, allophycocyanin-conjugated anti-CD11c, and biotinylated-anti-Kb. Staining with biotinylated mAb was revealed using allophycocyanin- or PE-conjugated streptavidin. The CD1d-specific mAb 5C6 and generation of CD1d/{alpha}-GalCer tetramer have been described previously (3, 37). Purified 5C6 and M5114 (anti-I-Ab) were conjugated to FITC or PE and used for staining. Murine IFN-beta, IFN-{gamma}, and the neutralizing anti-IFN-beta were obtained from PBL Biomedical Laboratories. Anti-TNF-{alpha} was obtained from the National Institutes of Health, whereas anti-IFN-{gamma} was purified from culture supernatants of hybridoma (XMG1.2) using protein A-Sepharose.

Bacteria and in vivo LM infection

The WT LM strain (1043S) and listeriolysin O-deficient (LLO– LM) strain was provided by Dr. H. Shen (University of Pennsylvania, Philadelphia, PA) and were grown in brain-heart infusion broth (Difco Laboratories). Mice were infected i.v. with 5 x 103 CFU in 100 µl of sterile PBS. The bacterial dose was verified by plating dilutions of the inoculum on brain-heart infusion agar plates. At day 1 postinfection, mice were sacrificed and peritoneal lavage, spleen, and liver cells were harvested and stained for flow cytometric analysis.

In vitro LM infection and cytokine treatment

BMDCs or DC2.4 cells were infected with either WT LM or LLO– LM for 1 h at a multiplicity of infection of 5:1 or 30:1, respectively. Cells were washed three times and cultured in RPMI 1640 medium containing 50 µg/ml gentamicin. After 16 h, culture supernatants and cells were collected. LM-infected or uninfected cells were washed and stained for relevant markers for flow cytometry analysis. For cytokine treatment, BMDCs or DC2.4 were incubated with indicated concentrations of recombinant IFN-beta or IFN-{gamma}. 16 h later, cells were washed and stained for flow cytometry.

Surface and intracellular staining

For surface staining, 2 x 105 cells were washed with FACS buffer (HBSS containing 2% FBS and 0.1% sodium azide) and incubated with 2.4G2 FcR blocking Ab for 5 min, followed by staining with saturating amounts of the mAbs for 45 min at 4°C. For intracellular staining, cells were fixed with 1% paraformaldehyde following surface staining for 1 h at room temperature. Cells were washed to remove fixative, followed by permeabilization in 0.3% saponin in PBS containing 10% FBS for 15 min at room temperature. Cells were then stained for 45 min at 4°C with specific mAbs in FACS buffer containing 0.3% saponin. After staining, cells were washed, resuspended in FACS buffer and examined in a FACSCalibur flow cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star).

RNA isolation and quantitative real-time PCR

DC2.4 cells with or without IFN-beta treatment were collected. Total RNA was isolated using TRIzol reagent (Invitrogen Life Technologies) following the instructions provided by the manufacturer. Total RNA (1.0 µg) from each sample was reverse transcribed to cDNA using Superscript reverse transcriptase (Invitrogen Life Technologies). Quantitative PCR was performed with the GeneAmp 7700 Sequence Detection System using SYBR Green PCR reagents according to the manufacturer’s instruction. All PCR were done in duplicate and the level of CD1d1 expression was normalized to GAPDH using Sequence Detector software (Applied Biosystems). PCR was performed with the following primer pairs: CD1d1 forward primer, 5'-GACACCTGCCCCCTATTTGT-3'; CD1d1 reverse primer, 5'-TGGCTTCTCTTGCTTCTCTAGGTC-3'; GAPDH forward primer, 5'-TTCACCACCATGGAGAAGGC-3'; GADPH reverse primer, 5'-GGCATGGACTGTGGTCATGA-3'; H2-Kb forward primer, 5'-GGTGGCTTTTGTGATGAAGATGAGAAGGAG-3'; and H2-Kb reverse primer, 5'-GTGCAGGGACAGGGTCCTGG-3'.

Immunofluorescence microscopy

IFN-beta-treated or untreated DC2.4 cells were allowed to adhere to the glass slides at 37°C. Cells were fixed in 3.7% paraformaldehyde for 15 min, quenched in 10 mM glycine for an additional 15 min and then permeabilized in PBS containing 0.3% saponin. For colocalization experiments, cells were labeled sequentially with FITC-conjugated anti-CD1d (5C6) and biotinylated anti-LAMP-1 on ice for 1 h. Cells were washed in buffer containing 0.3% saponin followed by staining with Texas Red-conjugated donkey anti-mouse IgG Ab. Confocal microscopy was performed on the labeled cells with Zeiss Axiovert 200. Images were collected using OpenLab (Improvision) at the indicated wavelengths. Stacks of optical sections were obtained, deconvoluted, and examined as single sections.

Internalization and recycling assays

The rate of internalization and recycling of CD1d were measured using flow cytometry based assays (38). IFN-beta-treated or untreated DC2.4 cells were incubated with 1 µg/ml 5C6-PE at 37°C. At the indicated times, aliquots were removed and divided into two parts. One part was left untreated on ice, while the other was incubated at 4°C for 45 s in PBS acidified to pH 2.0 with HCl and supplemented with 0.03 M sucrose and 10% FBS. Subsequently, samples were washed in a large excess of RPMI 1640 supplemented with 10% FBS and 100 mM HEPES buffer and analyzed by flow cytometry. Untreated samples account for total cell-associated fluorescence, while acid-stripped aliquots account for fluorescence in acid-resistant compartments. Results are expressed as the percent of internalization which is the ratio of acid-resistant (internal) to total PE fluorescence. For recycling, cells were incubated at 37°C with 5C6-PE for 40 min and acid stripped to remove all surface-bound Ab. Cells were resuspended in 37°C prewarmed culture medium in the presence or absence of IFN-beta and incubated at 37°C for the indicated time periods. Aliquots were either left untreated or acid stripped at the time points and results were expressed according to the equation: percentage of recycled = 1 – (acid resistant fluorescence/total cell-associated fluorescence).

Metabolic labeling and immunoprecipitation

DC2.4 cells were incubated in the presence or absence of IFN-beta for 16 h. After starving for 2 h in methionine/cysteine-free medium, cells were labeled with 0.4 mCi of [35S]translabel (MP Biomedicals) for 2 h. After washes, cells were chased in the presence of excess methionine and cysteine (1 mM) in complete RPMI 1640 medium for the indicated time periods. Cells were harvested and lysed in TBS containing 1% Nonidet P-40 and immunoprecipitated with anti-CD1d, anti-MHC class I, or control Ab-conjugated protein-A beads. Immunoprecipitates were separated by 12% SDS-PAGE and visualized by autoradiography.

In vitro NKT cell assays

Day 6 BMDCs were cultured in the presence or absence of 1000 U/ml IFN-beta for 16 h and used as stimulators. After washes, these stimulators were seeded (1 x 105/well) in U-bottom microtiter plates and incubated with anti-CD1d (5 µg) or a control Ab for 1 h at 37°C. A total of 1 x 105 hepatic lymphocytes isolated from V{alpha}14Tg mice were then added to the cultures. After 36 h, the culture supernatants were harvested and the levels of IL-4 and IFN-{gamma} were quantitated by sandwich ELISA (BD Pharmingen).

Statistical analysis

Mean values were compared using the unpaired Student’s t test. All statistical analyses were performed with the Prism program (GraphPad). Statistically significant differences p < 0.05 and p < 0.01 are noted with * and **, respectively.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
CD1d is up-regulated on APCs in LM-infected mice

iNKT cells can become activated as early as 1 day after LM infection as measured by CD69 up-regulation (Fig. 1A). It is possible that changes in CD1d expression levels may play a role in this response. To see whether LM infection indeed leads to CD1d up-regulation during early phase of infection, we examined CD1d expression levels in peritoneal lavage, where significant numbers of macrophages and DCs reside. As with iNKT cell activation, on day 1 after LM infection, CD1d up-regulation (3- to 4-fold) was readily detectable on both macrophages (F4/80+) and DCs (CD11c+) (Fig. 1B). To address the kinetics of CD1d induction during LM infection, we also examined CD1d expression on DCs and macrophages at different time points postinfection. We observed 5- to 6-fold higher levels of CD1d on DCs and macrophages at 3 days postinfection consistent with a previous report (39). These increased levels were sustained for up to 7 days postinfection. Interestingly, the level of CD1d expression on B and T cells is not altered in LM-infected mice (data not shown). These results indicate that LM infection results in preferential induction of CD1d on APCs early in infection.


Figure 1
View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 1. Effect of LM infection on CD1d expression and iNKT cell activation. B6 mice were infected i.v. with 5 x 103 CFU of LM. After 24 h, peritoneal lavage, spleen, and liver were isolated from both infected and uninfected mice. A, CD69 expression on CD1d/{alpha}-GalCer tetramer-positive cells from spleen and liver of uninfected (dotted line) and infected mice (thick line). B, Flow cytometric analysis of cell surface expression of CD1d on macrophages (F4/80+) and DCs (CD11c+) from peritoneal lavage. Fluorescence profiles of anti-CD1d staining from infected mice (thick line) and uninfected mice (dotted line) were overlaid with isotype control (filled gray histogram). Data are representative of at least two separate experiments.

 
LM infection up-regulates cell surface CD1d expression on DCs and macrophages

To examine whether up-regulation of CD1d surface expression is a direct result of LM infection of APCs, we performed in vitro LM infection studies on BMDC and analyzed CD1d expression by flow cytometry. We found that infection of BMDCs with LM results in a ~3-fold increase of CD1d surface expression (Fig. 2A). To rule out the possibility that CD1d up-regulation on BMDCs could occur indirectly through the effect of LM on some minor cell populations present in DC cultures, we performed similar in vitro infection studies using a DC line, DC2.4. As shown in Fig. 2A, surface CD1d expression is increased in the DC2.4 cell line 16 h after LM infection, indicating that infection of DCs with LM is sufficient to induce CD1d up-regulation. As both live and heat-killed LM (HKLM) can be internalized by DCs and up-regulate the expression of costimulatory molecules and MHC class II on DCs, we also examined the effect of HKLM on CD1d up-regulation on DCs. Unlike LM infection, incubating BMDCs or DC2.4 cells with HKLM does not lead to increased CD1d surface expression, suggesting that up-regulation of CD1d on LM-infected DCs is not due to the effects of microbial Ags on DC maturation (Fig. 2B).


Figure 2
View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 2. CD1d up-regulation by live LM is mediated by a secreted soluble factor. A, BMDCs (left) and DC2.4 cells (right) were infected with live LM (upper panels) or treated with LM-CM (lower panels). After 16 h, cells were stained for cell surface expression of CD1d. Representative histograms of CD1d expression on uninfected DCs (dotted line) and LM-infected or LM-CM treated DCs (thick line) and isotype control (filled gray histogram) are shown. B, Mean fluorescence intensity (MFI) of CD1d, assessed by flow cytometry, of BMDCs treated with either live LM, or HKLM, or conditioned medium derived from live LM-, HKLM-, or LLO– LM-infected cells. Data are presented as MFI after subtraction of isotype control. Values are mean ± SDs from three independent experiments.

 
CD1d induction during LM infection is mediated by IFN-beta

To explore the possibility that a soluble factor secreted by LM-infected DCs is responsible for up-regulation of CD1d, we tested whether LM-CM could induce CD1d up-regulation. Filtered LM-CM was fully able to induce up-regulation of CD1d on BMDCs and DC2.4 cells as compared with direct LM infection (Fig. 2A). Supernatants derived from bacterial cultures without DCs or from HKLM-treated DCs had little capacity to induce CD1d up-regulation (Fig. 2B), suggesting that the molecules that induce CD1d up-regulation were not produced by bacteria, but were secreted by DCs after LM infection.

To identify the secreted molecules produced by LM-infected DCs that mediated CD1d up-regulation, we looked for differential production of proinflammatory cytokines by treated DCs and examined the effect of these cytokines using specific neutralizing Abs. Consistent with a previous report (40), we detected comparable levels of IL-12 and TNF-{alpha} in conditioned medium from LM-infected DCs and HKLM-treated DCs (data not shown). In addition, no detectable amount of IFN-{gamma} was produced by DCs in response to HKLM treatment and LM infection. Because the production of IL-12, TNF-{alpha}, and IFN-{gamma} was similar after HKLM treatment or LM infection, they are unlikely to be responsible for the differences in CD1d up-regulation observed. Indeed, neutralizing Abs against TNF-{alpha}, IL-12, and IFN-{gamma} had very little or no effect on the activity of LM-CM in up-regulating the CD1d expression.

Recent studies have shown that infection with live but not HKLM induces DCs to secrete large amounts of IFN-beta (40). To determine whether IFN-beta is responsible for LM-CM mediated CD1d up-regulation, Abs to IFN-beta were used in blocking experiments. As shown in Fig. 3, neutralization of LM-CM with Abs to IFN-beta significantly blocked CD1d up-regulation. We also infected DC2.4 cells with LLO– LM, which lacks the ability to escape into the cytosol and is unable to induce IFN-beta in infected DCs (41). We found that supernatants derived from LLO– LM-infected DCs were unable to induce the up-regulation of CD1d, which further supports the role of IFN-beta in mediating the activity of LM-CM to induce CD1d up-regulation (Fig. 2B).


Figure 3
View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 3. CD1d up-regulation during LM infection is mediated by IFN-beta. DC2.4 cells were cultured overnight with conditioned medium from LM-infected cells incubated either in the presence or absence of neutralizing Abs against TNF-{alpha}, IFN-{gamma}, IFN-beta, and IL-12 for 14 h. The blocking efficacy of anti-TNF-{alpha}, anti-IFN-{gamma}, anti- IFN-beta, anti-IL-12, or a control IgG, either alone or in combination, on CD1d induction was examined. The extent of inhibition of CD1d up-regulation is expressed relative to CD1d levels observed in the absence of Ab. Data are shown as mean ± SD from three independent experiments. Statistically significant difference is indicated by asterisks as calculated by Student’s t test (**, p < 0.01).

 
rIFN-beta treatment up-regulates CD1d surface expression on APCs

To verify the direct effect of IFN-beta on surface expression of CD1d, DC2.4 cells were treated with titrating amounts of rIFN-beta for 16 h and CD1d surface expression was analyzed by flow cytometry. Fig. 4A shows a dose-dependent increase in CD1d expression on DC2.4 cells. The dose-response curve of IFN-beta plateaued at 1000 U/ml and resulted in an ~3-fold increase of CD1d surface expression on DC2.4 cells, comparable to that induced by LM-CM. The induction of CD1d was observed as early as 2 h after IFN-beta treatment and reached a plateau after 16 h of treatment, consistent with early in vivo up-regulation (Fig. 4A). Increased CD1d surface expression can also be detected in IFN-beta-treated BMDCs, peritoneal macrophages, and a macrophage cell line, P388 (Fig. 4C). Consistent with previous reports, the surface expression of MHC class Ia, H2-Kb, is also up-regulated in IFN-beta-treated DCs (data not shown) (42). As IFN-{gamma} has been shown to regulate CD1d expression on macrophages during mycobacteria infection, we compared the effect of IFN-beta and IFN-{gamma} on the surface expression of CD1d in BMDCs, DC2.4, and P388 cells. As shown in Fig. 4C, the extent of CD1d up-regulation induced by IFN-{gamma} treatment is much lower than that by IFN-beta in the time frame (16 h) examined.


Figure 4
View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 4. Recombinant mouse IFN-beta induces CD1d up-regulation on BMDCs, DC2.4, and P388 cells. A, DC2.4 cells were cultured with indicated concentrations of IFN-beta for 16 h before examining CD1d expression by flow cytometry. B, Time course of CD1d up-regulation during IFN-beta treatment (1000 U/ml) of DC2.4 cells. C, BMDCs and F4/80+ cells from peritoneal lavage were treated with IFN-beta (thick line) or medium alone (dotted line) and stained with anti-CD1d. The staining obtained with the control Ab is shown as a filled gray histogram. D, MFI values of BMDCs, DC2.4, and P388 cells after incubation with medium alone or with either IFN-beta or IFN-{gamma} (1000 U/ml) for 16 h. Mean ± SDs from three independent experiments are shown. Statistically significant difference is indicated by asterisks as calculated by Student’s t test (**, p < 0.01; *, p < 0.05).

 
Effect of IFN-beta on total protein and mRNA level of CD1d in DCs

To explore the mechanisms underlying the increased surface expression of CD1d by IFN-beta, we first examined whether the increase in surface CD1d expression is due to an increase in total protein levels of CD1d. To measure the steady state total CD1d levels, we performed immunofluorescence staining on permeabilized DC2.4 cells, followed by flow cytometric analysis. As shown in Fig. 5A, total CD1d levels are increased in the IFN-beta-treated cells as compared with the untreated cells. The extent of CD1d up-regulation is comparable to changes observed at the cell surface.


Figure 5
View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 5. IFN-beta increases total CD1d protein pool but does not affect the levels of CD1d mRNA. A, DC2.4 cells stimulated with or without IFN-beta for 16 h were stained with anti-CD1d for the surface expression followed by staining for intracellular CD1d. Total CD1d protein level was measured by flow cytometry. Data are presented as MFI after subtraction of isotype control. B, Total RNA was isolated from cells treated or not treated with IFN-beta. The CD1d mRNA (left) and H2-Kb mRNA levels (right) were measured by real-time PCR and normalized to GAPDH. Data are shown as mean ± SD from three independent experiments.

 
To test whether the increase in protein level of CD1d following IFN-beta treatment is associated with an increase in RNA level, real-time RT-PCR was performed using primers specific for CD1d1. As shown in Fig. 5B, CD1d message levels relative to a housekeeping gene (GAPDH) did not change after 16 h of IFN-beta treatment. In contrast, the level of H2-Kb mRNA was increased in IFN-beta-treated cells compared with untreated cells (Fig. 5B) These results indicate that increased expression of CD1d by IFN-beta is not regulated at the RNA level, unlike MHC class Ia.

IFN-beta does not alter intracellular trafficking of CD1d but induces de novo synthesis of CD1d

To examine whether IFN-beta treatment can affect the intracellular trafficking of CD1d, we examined the distribution of CD1d using confocal microscopy. Compared with untreated cells, IFN-beta-treated DC2.4 cells showed significantly brighter overall staining with anti-CD1d mAb, consistent with the notion that total pool of CD1d protein is increased in IFN-beta-treated cells (Fig. 6). However, the intracellular distribution of CD1d in IFN-beta-treated cells was similar to that in untreated cells, with a substantial amount of the intracellular CD1d colocalized with LAMP-1, a lysosomal marker (Fig. 6A). These results suggest that increased surface expression of CD1d by IFN-beta cannot be attributed to redistribution of the intracellular pool of CD1d. Furthermore, IFN-beta does not affect the rate of internalization and recycling of CD1d as measured by fluorescence-based assays (Fig. 6, B and C).


Figure 6
View larger version (47K):
[in this window]
[in a new window]
  		FIGURE 6. IFN-beta treatment does not affect the intracellular distribution, internalization, or recycling of CD1d. A, DC2.4 cells were cultured in the presence or absence of IFN-beta. Fluorescent confocal images of surface staining of CD1d are seen in the first set of top and bottom panels. Intracellular double staining of CD1d and LAMP-1 are shown separately in the next two sets of panels and colocalized images (merge) in the last panel. The cells were scanned using a x63 objective and the colocalization of CD1d in LAMP-1-positive compartments is evidenced by a yellow signal. B, Rate of internalization of CD1d in IFN-beta-treated and untreated DC2.4 cells was determined as described in Materials and Methods. Results are indicative of at least four independent experiments. C, Recycling rates of CD1d of IFN-beta-treated and untreated DC2.4 cells. Results are representative of at least three independent experiments.

 
To monitor the effect of IFN-beta on the biosynthesis and stability of CD1d, we performed pulse-chase experiments. DC2.4 cells were incubated with medium alone or with IFN-beta for 12 h, followed by pulse labeling for 2 h with [35S]translabel and chased for 0, 6, or 16 h in the presence or absence of IFN-beta. After cell lysis, total CD1d protein was immunoprecipitated with anti-CD1d Ab and analyzed by SDS-PAGE. Compared with untreated cells, the amount of newly synthesized CD1d was considerably greater in the IFN-beta-treated samples (t = 0), suggesting that IFN-beta enhanced the biosynthesis of CD1d protein. Comparing the ratio of CD1d between IFN-beta-treated and untreated cells at different times of chase revealed no clear changes in the half-life of CD1d in the IFN-beta-treated cells. Furthermore, we observed no significant difference in the acquisition of Endo H resistance between IFN-beta-treated and untreated samples (data not shown), confirming our confocal studies which showed that IFN-beta has no obvious effect on intracellular distribution of CD1d molecules. Thus, treatment of DC with IFN-beta appears to enhance the de novo synthesis of CD1d, but does not have a significant effect on the stability and intracellular transport of CD1d during the time period that we examined. For comparison, we also examined the effect of IFN-beta on the metabolism of H2-Kb. As shown in Fig. 7, IFN-beta treatment also increased biosynthesis of H2-Kb.


Figure 7
View larger version (52K):
[in this window]
[in a new window]
  		FIGURE 7. IFN-beta induces de novo synthesis of CD1d. IFN-beta-treated or untreated DC2.4 cells were metabolically labeled and chased for indicated time points (t = 0, 6, and 16 h) followed by immunoprecipitation with either anti-CD1d (top panel) or anti-H2-Kb (bottom panel) with appropriate controls. Bands corresponding to CD1d or Kb H chains and beta2m are indicated by arrows.

 
IFN-beta-treated DCs induce iNKT cell activation

To test whether IFN-beta mediated increase in surface CD1d expression is associated with an altered ability of DCs to stimulate iNKT cells, IFN-beta-treated and untreated DCs were cultured with iNKT cells freshly isolated from V{alpha}14Tg mice and cytokine production was measured after 48 h. We found that iNKT cells produce significantly higher amounts of IL-4 and IFN-{gamma} in response to stimulation by IFN-beta-treated DCs, while no noticeable amounts of IFN-{gamma} and IL-4 can be detected from iNKT cells stimulated with untreated DCs (Fig. 8). The cytokine response to IFN-beta-treated DCs can be blocked by anti-CD1d, indicating this activation process is CD1d dependent. Although IFN-beta has been shown to induce the expression of some costimulatory molecules, we did not detect significant changes on the expression of CD80, CD40, and CD86 during the time frame (16 h) used to induce CD1d up-regulation (data not shown). Thus, the observed difference in cytokine production in response to IFN-beta-treated DCs compared with untreated DCs is likely due, at least in part, to the increase in surface CD1d expression seen in IFN-beta-treated DCs.


Figure 8
View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 8. Activation of NKT cells by increased CD1d levels. BMDCs derived from wild-type or Kb-CD1dTg mice were used as stimulators. Wild-type BMDCs were either untreated or treated with IFN-beta for 16 h. Liver NKT cells from V{alpha}14Tg mice were incubated with equal numbers of different stimulators indicated above in the presence of either anti-CD1d or control IgG. After 36 h, supernatants were collected and analyzed for IL-4 and IFN-{gamma} by ELISA. Results are representative of two separate experiments. Statistically significant difference is indicated by asterisks as calculated by Student’s t test (**, p < 0.01; *, p < 0.05).

 
To directly address the question of whether increased CD1d surface expression is sufficient to lead to iNKT cell activation, we used BMDCs from Kb-CD1dTg mice, which express CD1d under the control of the H2-Kb promoter. The cell surface level of CD1d on Kb-CD1dTg+ BMDCs is 5- to 6-fold higher that that of WT BMDCs, while the expression of other DC maturation markers is similar (data not shown). As shown in Fig. 8, iNKT cells stimulated with Kb-CD1dTg+ BMDCs produced even greater amounts of IFN-{gamma} and IL-4 than IFN-beta-treated DCs, possibly due to their higher CD1d expression levels. These data demonstrate that increased CD1d surface expression on DCs is associated with enhanced cytokine secretion by iNKT cells, suggesting that up-regulation of CD1d expression during infection or inflammatory conditions may play a role in regulating the function of iNKT cells.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
Up-regulation of MHC class I expression during infection has been shown to be largely mediated by cytokines, in particular IFNs and TNF-{alpha} (43, 44). Increased levels of MHC class I can lead to more effective recognition of infected cells by CD8+ T cells and promote cytolytic responses against intracellular pathogens. Recent studies have shown that iNKT cells are activated early during infection and may participate in host defense against a wide range of pathogens (1, 22, 30). However, little is known about how expression of CD1d is regulated during infection. In this study, we demonstrated that LM infection induced CD1d up-regulation on DCs and macrophages both in vivo and in vitro. IFN-beta secreted by LM-infected APCs was the major factor responsible for CD1d up-regulation during LM infection. Neutralizing Abs against IFN-beta could abrogate the effect of LM-mediated CD1d up-regulation; rIFN-beta treatment enhanced CD1d expression to the levels similar to those induced by LM infection. This is, to our knowledge, the first study to demonstrate that IFN-beta mediates CD1d expression in response to an infectious agent.

IFN-beta treatment augments the biosynthesis of CD1d protein, but has no significant effect on the steady state levels of CD1d mRNA, suggesting a posttranscriptional regulatory mechanism that is distinct from the regulation of MHC class I. Our finding that IFN-beta-treated DCs and Kb-CD1dTg+ DCs, but not untreated WT DCs, induced significant cytokine production from iNKT cells in the absence of exogenous Ags suggests that up-regulated CD1d levels on DCs are sufficient to activate NKT cells in vitro. The preferential induction of CD1d expression on DCs and macrophages in LM-infected mice is noteworthy. CD1d up-regulation can be detected as early as 24 h after LM infection, concomitant with the activation of iNKT cells, suggesting increased CD1d expression during infection may have functional consequences.

Cytokines and microbial signals have been implicated in CD1d induction during infection. TNF-{alpha} has been shown to be necessary, but not sufficient, for CD1d induction in coxsackievirus B3-infected endothelial cells (45). A recent study on M. tuberculosis infection demonstrated a synergistic effect of IFN-{gamma} and TNF-{alpha} on CD1d induction on macrophages (30). Our Ab-blocking experiment, however, suggests that IFN-{gamma} and TNF-{alpha} do not contribute significantly to CD1d up-regulation in the LM infection model. This result is further substantiated by the findings that LM infection of IFN-{gamma} knockout (KO) BMDCs and WT DCs resulted in similar levels of CD1d up-regulation (data not shown). Furthermore, treatment of TNFRKO BMDCs with conditioned medium derived from LM-infected cells resulted in increased CD1d levels, comparable to WT BMDCs (data not shown). Thus, it is possible that different pathogens may use distinct mechanisms to modulate the expression of CD1d.

IFN-beta, a type I IFN, is rapidly induced in response to viral infection but can also be produced upon exposure to nonviral pathogens, such as LM (40), M. tuberculosis (46), Chlamydia trachomatis (47), and Schistosoma mansoni (48). The specific induction of CD1d on APCs but not T cells by IFN-beta strongly supports a role for NKT cells in infectious response. Thus, it is conceivable that LM-induced CD1d up-regulation by IFN-beta can be extended to other pathogens, implying a broad role for CD1d up-regulation in early infectious response.

In addition, early IFN-beta production has been shown to promote the subsequent expression of additional type I IFN genes during infection through a positive feedback mechanism (49, 50). The mouse type I IFN locus contains 14 IFN-{alpha} genes and single IFN-beta, IFN-{kappa}, and IFN-{epsilon} genes, which have different binding affinities to the common IFN-{alpha}/IFN-beta receptor, perhaps leading to differential signaling and gene activation (51, 52). It is thus likely that these other type I IFN subtypes may be involved in CD1d regulation as well.

Binding of IFN-beta to IFN-{alpha}/IFN-beta receptor leads to activation of JAK-STAT signaling pathways and the formation of the heterotrimeric transcription factor complex, IFN-stimulated gene factor 3 (ISGF3), which binds to and transactivates genes containing IFN-stimulated response element (53). IFN-beta can also activate the formation of STAT-1 homodimer, which binds to a {gamma}-activated site in the promoters of IFN-responsive genes to mediate an overlapping set of response with IFN-{gamma}. Our finding that rIFN-beta has a more profound effect on the up-regulation of CD1d expression than IFN-{gamma} suggests that ISGF3 is involved in this process. An analysis of CD1d1 sequence shows that no IFN-stimulated response element is present in the proximal promoter region of CD1d1 (54), however, suggesting CD1d1 is not a direct target of ISGF3. This may explain the absence of transcriptional changes in CD1d after IFN-beta treatment in the cell lines examined. ISGF3 target genes may instead mediate posttranscriptional regulation of CD1d expression.

CD1d, like MHC class II molecules, survey Ags in the endocytic pathway. It has been reported that the MHC class II-invariant chain complex interacts with CD1d and affects the intracellular distribution of CD1d (9, 55). Thus, it has been postulated that the expression and intracellular trafficking of CD1d may be altered by MHC class II molecules and invariant chain induced during inflammation. Although IFN-{gamma} can induce the expression of MHC class II, type I IFNs have not been shown to be involved in the up-regulation of MHC class II (56, 57). Indeed, we did not detect significant difference in MHC class II expression in IFN-beta-treated BMDCs (data not shown). Furthermore, the degree of CD1d up-regulation by IFN-beta is similar between WT and MHC class II-deficient DCs (data not shown), indicating that the observed effect of IFN-beta on CD1d expression is independent of the expression and intracellular trafficking of MHC class II.

Modulation of surface CD1d expression levels has been shown to have a direct effect on the numbers, activation, and function of CD1d-restricted iNKT cells. For example, TGF-beta synthesized by human keratinocytes has been shown to have an inhibitory role on the proliferation and differentiation of CD1d-restricted NKT cells (58). This effect correlates to decreased expression of human CD1d on DCs being mediated by TGF-beta. Biliary CD1d up-regulation and increased numbers of hepatic iNKT cells have been observed in primary biliary cirrhosis (59). In addition, up-regulation of CD1d on macrophages during M. tuberculosis infection is able to induce NKT cell activation both in vivo and in vitro (30). Therefore, although we cannot exclude the possibility of presentation of specific listerial Ags to NKT cells, IFN-beta-mediated increase in CD1d levels on DCs may indeed be one possible mechanism to activate iNKT cells during infection.

Besides being promptly induced in response to microbial pathogens, IFN-beta is widely used for clinical treatment of several human pathologies such as infectious diseases, multiple sclerosis, or tumors (60, 61). NKT cells have been shown to have strong functional roles in either pathology or amelioration of disease (22). Up-regulation of CD1d expression by IFN-beta may thus inadvertently strengthen or impair immune responses in these patients. Understanding the regulation of CD1d expression as well as the functional consequence of this regulation on iNKT cells by IFN-beta may therefore lead to a better understanding of the current role of IFN-beta in the clinical setting as well as potential extension of this treatment to other diseases.


   Acknowledgments
 
We thank Drs. Angela Colmone, Mike Zimmer, Honglin Xu, and Hak-Jong Choi for critical reading of the manuscript, Dr. Yan-Xin Fu (University of Chicago) for providing TNFRKO mice, and Shirley Bond for advice on confocal microscopy.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Grant R01 AI43407 (to C.-R.W.). Back

2 Address correspondence and reprint requests to Dr. Chyung-Ru Wang, Department of Pathology, University of Chicago, 924 East 57th Street, Biological Sciences Learning Center, Room 116, Chicago, IL 60637-5420. E-mail address: cwang{at}uchicago.edu Back

3 Abbreviations used in this paper: DC, dendritic cell; beta2m, beta2-microglobulin; iNKT, invariant NKT; {alpha}-GalCer, {alpha}-galactosylceramide; LM, Listeria monocytogenes; WT, wild type; BMDC, bone marrow-derived DC; HKLM, heat-killed LM; ISGF3, IFN-stimulated gene factor 3; KO, knockout; LM-CM, conditioned medium from LM-infected DC. Back

Received for publication May 30, 2006. Accepted for publication September 11, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Brigl, M., M. B. Brenner. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22: 817-890. [Medline]
  2. Park, S. H., J. H. Roark, A. Bendelac. 1998. Tissue-specific recognition of mouse CD1 molecules. J. Immunol. 160: 3128-3134. [Abstract/Free Full Text]
  3. Mandal, M., X. R. Chen, M. L. Alegre, N. M. Chiu, Y. H. Chen, A. R. Castano, C. R. Wang. 1998. Tissue distribution, regulation and intracellular localization of murine CD1 molecules. Mol. Immunol. 35: 525-536. [Medline]
  4. Martin, L. H., F. Calabi, C. Milstein. 1986. Isolation of CD1 genes: a family of major histocompatibility complex-related differentiation antigens. Proc. Natl. Acad. Sci. USA 83: 9154-9158. [Abstract/Free Full Text]
  5. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al 1997. CD1d-restricted and TCR-mediated activation of v{alpha}14 NKT cells by glycosylceramides. Science 278: 1626-1629. [Abstract/Free Full Text]
  6. Sugita, M., X. Cao, G. F. Watts, R. A. Rogers, J. S. Bonifacino, M. B. Brenner. 2002. Failure of trafficking and antigen presentation by CD1 in AP-3-deficient cells. Immunity 16: 697-706. [Medline]
  7. Brozovic, S., T. Nagaishi, M. Yoshida, S. Betz, A. Salas, D. Chen, A. Kaser, J. Glickman, T. Kuo, A. Little, et al 2004. CD1d function is regulated by microsomal triglyceride transfer protein. Nat. Med. 10: 535-539. [Medline]
  8. Dougan, S. K., A. Salas, P. Rava, A. Agyemang, A. Kaser, J. Morrison, A. Khurana, M. Kronenberg, C. Johnson, M. Exley, et al 2005. Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. J. Exp. Med. 202: 529-539. [Abstract/Free Full Text]
  9. Kang, S. J., P. Cresswell. 2004. Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nat. Immunol. 5: 175-181. [Medline]
  10. Zhou, D., C. Cantu, III, Y. Sagiv, N. Schrantz, A. B. Kulkarni, X. Qi, D. J. Mahuran, C. R. Morales, G. A. Grabowski, K. Benlagha, et al 2004. Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 303: 523-527. [Abstract/Free Full Text]
  11. Arase, H., N. Arase, K. Ogasawara, R. A. Good, K. Onoe. 1992. An NK1.1+CD4+8– single-positive thymocyte subpopulation that expresses a highly skewed T-cell antigen receptor Vbeta family. Proc. Natl. Acad. Sci. USA 89: 6506-6510. [Abstract/Free Full Text]
  12. Godfrey, D. I., H. R. MacDonald, M. Kronenberg, M. J. Smyth, L. Van Kaer. 2004. NKT cells: what’s in a name?. Nat. Rev. Immunol. 4: 231-237. [Medline]
  13. Kronenberg, M.. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23: 877-900. [Medline]
  14. Exley, M., J. Garcia, S. P. Balk, S. Porcelli. 1997. Requirements for CD1d recognition by human invariant V{alpha}24+CD4–CD8– T cells. J. Exp. Med. 186: 109-120. [Abstract/Free Full Text]
  15. Carnaud, C., D. Lee, O. Donnars, S. H. Park, A. Beavis, Y. Koezuka, A. Bendelac. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163: 4647-4650. [Abstract/Free Full Text]
  16. Fujii, S., K. Shimizu, C. Smith, L. Bonifaz, R. M. Steinman. 2003. Activation of natural killer T cells by {alpha}-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198: 267-279. [Abstract/Free Full Text]
  17. Singh, N., S. Hong, D. C. Scherer, I. Serizawa, N. Burdin, M. Kronenberg, Y. Koezuka, L. Van Kaer. 1999. Cutting edge: activation of NK T cells by CD1d and {alpha}-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol. 163: 2373-2377. [Abstract/Free Full Text]
  18. Behar, S. M., T. A. Podrebarac, C. J. Roy, C. R. Wang, M. B. Brenner. 1999. Diverse TCRs recognize murine CD1. J. Immunol. 162: 161-167. [Abstract/Free Full Text]
  19. Cardell, S., S. Tangri, S. Chan, M. Kronenberg, C. Benoist, D. Mathis. 1995. CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J. Exp. Med. 182: 993-1004. [Abstract/Free Full Text]
  20. Park, S. H., A. Weiss, K. Benlagha, T. Kyin, L. Teyton, A. Bendelac. 2001. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J. Exp. Med. 193: 893-904. [Abstract/Free Full Text]
  21. Exley, M. A., N. J. Bigley, O. Cheng, S. M. Tahir, S. T. Smiley, Q. L. Carter, H. F. Stills, M. J. Grusby, Y. Koezuka, M. Taniguchi, S. P. Balk. 2001. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J. Leukocyte Biol. 69: 713-718. [Abstract/Free Full Text]
  22. Hansen, D. S., L. Schofield. 2004. Regulation of immunity and pathogenesis in infectious diseases by CD1d-restricted NKT cells. Int. J. Parasitol. 34: 15-25. [Medline]
  23. Kinjo, Y., M. Kronenberg. 2005. V{alpha}14i NKT cells are innate lymphocytes that participate in the immune response to diverse microbes. J. Clin. Immunol. 25: 522-533. [Medline]
  24. Brigl, M., L. Bry, S. C. Kent, J. E. Gumperz, M. B. Brenner. 2003. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4: 1230-1237. [Medline]
  25. Fischer, K., E. Scotet, M. Niemeyer, H. Koebernick, J. Zerrahn, S. Maillet, R. Hurwitz, M. Kursar, M. Bonneville, S. H. Kaufmann, U. E. Schaible. 2004. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc. Natl. Acad. Sci. USA 101: 10685-10690. [Abstract/Free Full Text]
  26. Kinjo, Y., D. Wu, G. Kim, G. W. Xing, M. A. Poles, D. D. Ho, M. Tsuji, K. Kawahara, C. H. Wong, M. Kronenberg. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520-525. [Medline]
  27. Sriram, V., W. Du, J. Gervay-Hague, R. R. Brutkiewicz. 2005. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur. J. Immunol. 35: 1692-1701. [Medline]
  28. Mattner, J., K. L. Debord, N. Ismail, R. D. Goff, C. Cantu, III, D. Zhou, P. Saint-Mezard, V. Wang, Y. Gao, N. Yin, et al 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434: 525-529. [Medline]
  29. Berntman, E., J. Rolf, C. Johansson, P. Anderson, S. L. Cardell. 2005. The role of CD1d-restricted NK T lymphocytes in the immune response to oral infection with Salmonella typhimurium. Eur. J. Immunol. 35: 2100-2109. [Medline]
  30. Skold, M., X. Xiong, P. A. Illarionov, G. S. Besra, S. M. Behar. 2005. Interplay of cytokines and microbial signals in regulation of CD1d expression and NKT cell activation. J. Immunol. 175: 3584-3593. [Abstract/Free Full Text]
  31. Durante-Mangoni, E., R. Wang, A. Shaulov, Q. He, I. Nasser, N. Afdhal, M. J. Koziel, M. A. Exley. 2004. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J. Immunol. 173: 2159-2166. [Abstract/Free Full Text]
  32. Sanchez, D. J., J. E. Gumperz, D. Ganem. 2005. Regulation of CD1d expression and function by a herpesvirus infection. J. Clin. Invest. 115: 1369-1378. [Medline]
  33. Lara-Tejero, M., E. G. Pamer. 2004. T cell responses to Listeria monocytogenes. Curr. Opin. Microbiol. 7: 45-50. [Medline]
  34. Ranson, T., S. Bregenholt, A. Lehuen, O. Gaillot, M. C. Leite-de-Moraes, A. Herbelin, P. Berche, J. P. Di Santo. 2005. Invariant V{alpha}14+ NKT cells participate in the early response to enteric Listeria monocytogenes infection. J. Immunol. 175: 1137-1144. [Abstract/Free Full Text]
  35. Chun, T., M. J. Page, L. Gapin, J. L. Matsuda, H. Xu, H. Nguyen, H. S. Kang, A. K. Stanic, S. Joyce, W. A. Koltun, et al 2003. CD1d-expressing dendritic cells but not thymic epithelial cells can mediate negative selection of NKT cells. J. Exp. Med. 197: 907-918. [Abstract/Free Full Text]
  36. Shen, Z., G. Reznikoff, G. Dranoff, K. L. Rock. 1997. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158: 2723-2730. [Abstract]
  37. Matsuda, J. L., O. V. Naidenko, L. Gapin, T. Nakayama, M. Taniguchi, C. R. Wang, Y. Koezuka, M. Kronenberg. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192: 741-754. [Abstract/Free Full Text]
  38. Cefai, D., H. Schneider, O. Matangkasombut, H. Kang, J. Brody, C. E. Rudd. 1998. CD28 receptor endocytosis is targeted by mutations that disrupt phosphatidylinositol 3-kinase binding and costimulation. J. Immunol. 160: 2223-2230. [Abstract/Free Full Text]
  39. Szalay, G., C. H. Ladel, C. Blum, L. Brossay, M. Kronenberg, S. H. Kaufmann. 1999. Cutting edge: anti-CD1 monoclonal antibody treatment reverses the production patterns of TGF-beta 2 and Th1 cytokines and ameliorates listeriosis in mice. J. Immunol. 162: 6955-6958. [Abstract/Free Full Text]
  40. Feng, H., D. Zhang, D. Palliser, P. Zhu, S. Cai, A. Schlesinger, L. Maliszewski, J. Lieberman. 2005. Listeria-infected myeloid dendritic cells produce IFN-beta, priming T cell activation. J. Immunol. 175: 421-432. [Abstract/Free Full Text]
  41. McCaffrey, R. L., P. Fawcett, M. O’Riordan, K. D. Lee, E. A. Havell, P. O. Brown, D. A. Portnoy. 2004. A specific gene expression program triggered by Gram-positive bacteria in the cytosol. Proc. Natl. Acad. Sci. USA 101: 11386-11391. [Abstract/Free Full Text]
  42. Dhib-Jalbut, S. S., E. P. Cowan. 1993. Direct evidence that interferon-beta mediates enhanced HLA-class I expression in measles virus-infected cells. J. Immunol. 151: 6248-6258. [Abstract]
  43. Leeuwenberg, J. F., J. van Damme, G. M. Jeunhomme, W. A. Buurman. 1987. Interferon beta1, an intermediate in the tumor necrosis factor {alpha}-induced increased MHC class I expression and an autocrine regulator of the constitutive MHC class I expression. J. Exp. Med. 166: 1180-1185. [Abstract/Free Full Text]
  44. Pamer, E., P. Cresswell. 1998. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16: 323-358. [Medline]
  45. Huber, S. A., D. Sartini. 2005. Roles of tumor necrosis factor {alpha} (TNF-{alpha}) and the p55 TNF receptor in CD1d induction and coxsackievirus B3-induced myocarditis. J. Virol. 79: 2659-2665. [Abstract/Free Full Text]
  46. Remoli, M. E., E. Giacomini, G. Lutfalla, E. Dondi, G. Orefici, A. Battistini, G. Uze, S. Pellegrini, E. M. Coccia. 2002. Selective expression of type I IFN genes in human dendritic cells infected with Mycobacterium tuberculosis. J. Immunol. 169: 366-374. [Abstract/Free Full Text]
  47. Nagarajan, U. M., D. M. Ojcius, L. Stahl, R. G. Rank, T. Darville. 2005. Chlamydia trachomatis induces expression of IFN-{gamma}-inducible protein 10 and IFN-beta independent of TLR2 and TLR4, but largely dependent on MyD88. J. Immunol. 175: 450-460. [Abstract/Free Full Text]
  48. Trottein, F., N. Pavelka, C. Vizzardelli, V. Angeli, C. S. Zouain, M. Pelizzola, M. Capozzoli, M. Urbano, M. Capron, F. Belardelli, et al 2004. A type I IFN-dependent pathway induced by Schistosoma mansoni eggs in mouse myeloid dendritic cells generates an inflammatory signature. J. Immunol. 172: 3011-3017. [Abstract/Free Full Text]
  49. Stockinger, S., B. Reutterer, B. Schaljo, C. Schellack, S. Brunner, T. Materna, M. Yamamoto, S. Akira, T. Taniguchi, P. J. Murray, et al 2004. IFN regulatory factor 3-dependent induction of type I IFNs by intracellular bacteria is mediated by a TLR- and Nod2-independent mechanism. J. Immunol. 173: 7416-7425. [Abstract/Free Full Text]
  50. Marie, I., J. E. Durbin, D. E. Levy. 1998. Differential viral induction of distinct interferon-{alpha} genes by positive feedback through interferon regulatory factor-7. EMBO J. 17: 6660-6669. [Medline]
  51. Pestka, S., J. A. Langer, K. C. Zoon, C. E. Samuel. 1987. Interferons and their actions. Annu. Rev. Biochem. 56: 727-777. [Medline]
  52. Platanias, L. C.. 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5: 375-386. [Medline]
  53. Decker, T., S. Stockinger, M. Karaghiosoff, M. Muller, P. Kovarik. 2002. IFNs and STATs in innate immunity to microorganisms. J. Clin. Invest. 109: 1271-1277. [Medline]
  54. Geng, Y., P. Laslo, K. Barton, C. R. Wang. 2005. Transcriptional regulation of CD1D1 by Ets family transcription factors. J. Immunol. 175: 1022-1029. [Abstract/Free Full Text]
  55. Jayawardena-Wolf, J., K. Benlagha, Y. H. Chiu, R. Mehr, A. Bendelac. 2001. CD1d endosomal trafficking is independently regulated by an intrinsic CD1d-encoded tyrosine motif and by the invariant chain. Immunity 15: 897-908. [Medline]
  56. Blumberg, R. S., L. J. Saubermann, W. Strober. 1999. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr. Opin. Immunol. 11: 648-656. [Medline]
  57. Honda, K., S. Sakaguchi, C. Nakajima, A. Watanabe, H. Yanai, M. Matsumoto, T. Ohteki, T. Kaisho, A. Takaoka, S. Akira, et al 2003. Selective contribution of IFN-{alpha}/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc. Natl. Acad. Sci. USA 100: 10872-10877. [Abstract/Free Full Text]
  58. Ronger-Savle, S., J. Valladeau, A. Claudy, D. Schmitt, J. Peguet-Navarro, C. Dezutter-Dambuyant, L. Thomas, D. Jullien. 2005. TGFbeta inhibits CD1d expression on dendritic cells. J. Invest. Dermatol. 124: 116-118. [Medline]
  59. Tsuneyama, K., M. Yasoshima, K. Harada, K. Hiramatsu, M. E. Gershwin, Y. Nakanuma. 1998. Increased CD1d expression on small bile duct epithelium and epithelioid granuloma in livers in primary biliary cirrhosis. Hepatology 28: 620-623. [Medline]
  60. Bogdan, C.. 2000. The function of type I interferons in antimicrobial immunity. Curr. Opin. Immunol. 12: 419-424. [Medline]
  61. Biron, C. A.. 2001. Interferons {alpha} and beta as immune regulators—a new look. Immunity 14: 661-664. [Medline]



This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
H.-J. Choi, H. Xu, Y. Geng, A. Colmone, H. Cho, and C.-R. Wang
Bacterial infection alters the kinetics and function of iNKT cell responses
J. Leukoc. Biol., December 1, 2008; 84(6): 1462 - 1471.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Salio, A. O. Speak, D. Shepherd, P. Polzella, P. A. Illarionov, N. Veerapen, G. S. Besra, F. M. Platt, and V. Cerundolo
Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation
PNAS, December 18, 2007; 104(51): 20490 - 20495.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raghuraman, G.
Right arrow Articles by Wang, C.-R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raghuraman, G.
Right arrow Articles by Wang, C.-R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS